Asembia Specialty Pharmacy Summit

One notable incentive includes the launch of biosimilars at both low- and high wholesale acquisition costs.

Pharmacists can help financial decision makers understand the value of biosimilar therapies.

Savings associated with biosimilar uptake are projected to reach $181 billion through 2027.

The role of health care specialty pharmacies has expanded.

The expertise of health system specialty pharmacists, combined with better adherence and better affordability, leads to better patient outcomes.

Paying for these new therapies, that may be curative for patients, remains a challenge.

From medication adherence to patient counseling, clinical pharmacists at health system specialty pharmacies can play a role in reducing health care costs.

Adam Fein, Ph.D., talked about some surprising trends in specialty pharmacy and healthcare at the 2023 Asembia Specialty Pharmacy Summit. The number of specialty pharmacy locations may be peaking. And that "gross-to-net bubble" in drug prices that Fein has written about so much — well, it may be shrinking.

Parcel tracking technology that used predictive analytics can help with real-time package delivery monitoring and ensure on-time delivery.

Discussions around women’s health should extend beyond talking about menstruation and pregnancy to include all aspects of health.

Juliana Reed, executive director of the Biosimilars Forum, discussed the impact of market dynamics and changing pricing structures during a presentation at the 2023 Asembia Specialty Pharmacy Summit.

Research shows that patient experiences and sometimes outcomes are improved when they are treated by health care professions from similar communities.

Although there’s a greater trend toward digital communication and monitoring tools, patient trust needs to extend beyond the health care system and their providers.

The specialty drug pipeline is projected to grow by 8% each year through 2025.

88% of surveyed payers said interchangeability will have the biggest impact on adoption.

The Inflation Reduction Act boosted the Medicare payment for biosimilars from the standard average sales price plus 6% to 8%.

At the 2019 Asembia Specialty Pharmacy Summit, former FDA Commissioner Scott Gottlieb discussed advances within the agency during his tenure.